Travere Therapeutics, Inc. TVTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$37.1M— | —— | $25.71M+302% | -$12.76M+69.1% | -$41.23M+31.6% | ||
| $25.21M+39.0% | $18.14M+14.9% | $15.79M+12.6% | $14.02M+9.5% | $12.8M+5.9% | ||
| $16.15M+40.8% | $11.46M+1.8% | $11.26M+5.8% | $10.65M-7.3% | $11.49M+24.7% | ||
| $7.23M— | —— | $44.16M+931% | $4.28M-40.6% | $7.2M+263% | ||
| $742K+163% | -$1.18M-507% | -$194K— | $0+100% | -$3.66M-1,386% | ||
| -$11.81M— | —— | -$1.11M— | —— | -$8.31M— | ||
| -$20.9M-221% | $17.34M-12.0% | $19.7M+1,372% | $1.34M+114% | -$9.54M— | ||
| $6.38M— | $0-100% | $1.33M-74.0% | $5.11M+206% | $1.67M— | ||
| $1.94M+429% | -$589K+94.5% | -$10.64M-1,403% | $816K+15.1% | $709K-3.8% | ||
| $4K— | —— | $807K— | —— | $1.57M+154% | ||
| $0— | —— | —— | -$1.47M-8.7% | -$1.35M-141% | ||
| -$40.37M-167% | $60.68M— | —— | —— | -$42.19M-18.1% | ||
| $48.78M-40.8% | $82.42M-22.7% | $106.62M+31.0% | $81.4M+53.1% | $53.16M-3.4% | ||
| $22.18M+15.3% | $19.24M+27.9% | $15.05M+24.5% | $12.09M+2.6% | $11.78M+22.2% | ||
| $21.55M— | —— | $86.59M+1,685% | $4.85M-88.3% | $41.29M— | ||
| $4.73M+154% | -$8.8M-315% | $4.09M+783% | $463K-89.1% | $4.24M-96.8% | ||
| $4.2M— | —— | -$65.34M-4,530% | $1.48M-60.3% | $3.72M-97.3% | ||
| -$60K— | —— | $207K-89.4% | $1.95M+256% | $548K+157% | ||
| -$14.67M— | —— | $35.78M+170% | $13.26M+294% | $3.36M-84.8% | ||
| —— | $2.21M0.0% | $2.21M0.0% | $2.21M0.0% | $2.21M0.0% | ||
| -$20.9M-221% | $17.34M-12.0% | $19.7M+1,372% | $1.34M+114% | -$9.54M— | ||
| $6.38M— | $0-100% | $1.33M-74.0% | $5.11M+206% | $1.67M— | ||
| $4K— | —— | $807K— | —— | $1.57M+154% | ||
| $0-100% | $470K+15,767% | -$3K+97.9% | -$146K-276% | $83K+108% | ||
| $22.18M+15.3% | $19.24M+27.9% | $15.05M+24.5% | $12.09M+2.6% | $11.78M+22.2% | ||
| $48.78M-40.8% | $82.42M-22.7% | $106.62M+31.0% | $81.4M+53.1% | $53.16M-3.4% | ||
| —— | $3.57M0.0% | $3.57M0.0% | $3.57M0.0% | $3.57M-7.5% | ||
| —— | $1.64M0.0% | $1.64M0.0% | $1.64M0.0% | $1.64M+2.9% | ||
| $525K0.0% | $525K0.0% | $525K0.0% | $525K0.0% | $525K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.